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John R. Wingard,23 J. Douglas Rizzo,7 Navneet S. Majhail24Preservation of fertility after hematopoietic cell transplantation (HCT) can have a significant influence on the
quality of life of transplant survivors. We describe 178 pregnancies in HCTrecipients that were reported to
the Center for International Blood and Marrow Transplant Research (CIBMTR) between 2002 and 2007.
There were 83 pregnancies in female HCT recipients and 95 pregnancies in female partners of male HCT
recipients. Indications for transplantation included hematologic and other malignancies (N 5 99) and non-
malignant disorders (N 5 79, of which 75 patients had severe aplastic anemia). The cohort included recip-
ients of autologous HCT (20 women, 13 men), myeloablative (MA) allogeneic HCT (12 women, 50 men), and
nonmyeloablative allogeneic HCT (2 women, 2 men). Age at HCTwas\20 years for 50% of women and 19%
of men. Conditioning regimens included total body irradiation (TBI) in 16% of women and 19% of men; doses
were MA in 10% of women and in 16% of men. Live births were reported in 86% of pregnancies in partners of
male transplant patients and 85% of pregnancies in female transplant patients, with most pregnancies occur-
ring 5 to 10 years after HCT. We conclude that some HCTrecipients can retain fertility, including patients
who have received TBI and/or MA conditioning. Young patients undergoing HCT should be counseled both
before and after HCTabout potential loss of fertility, methods for preserving fertility, and planning for future
pregnancy. Fertility and outcomes of pregnancy after HCT need prospective evaluation in large transplant
cohorts.
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Long-term survivors of hematopoietic cell trans-
plantation (HCT) are increasing in number because
of improved transplant outcomes and better supportive
care. In addition, the expanding indications for trans-
plantation have led to an increase in the number of
patients receiving HCT. Hence, quality of life after
HCT is of greater concern. Among young patients,
fertility preservation after transplantation canhave a sig-
nificant influence on quality of life [1,2]. Infertility is
a frequently reported ‘‘loss’’ experienced by HCT
recipients, especially by women [3]. HCT recipients
may already be at high risk for gonadal damage and in-
fertility from previous exposure to chemotherapy and
irradiation during pretransplant therapies. These risks
are further increased by most transplant conditioning
regimens [4-9].
Successful pregnancies have been reported in
female HCT recipients and in female partners of male
HCT recipients [4,10-15]. The 2 largest studies are
from the European Group for Blood and Marrow
Transplantation (EBMT) and the Bone Marrow
Transplant Survivor Study (BMTSS). Salooja et al.
[12] addressed this issue in the EBMT by sending ques-
tionnaires to 199 centers relating to nearly 38,000
transplants (autologous and allogeneic) inquiring about
pregnancy rates in their posttransplant patients. They
included data on patients who had conceived via assis-
ted reproductive technologies (ART) as well as those
who conceived naturally. They reported 312 pregnan-
cies from 232 patients, for an overall conception rate
of 0.6%. Overall, the authors found that the frequency
of pregnancy complications was much higher in female
allograft recipients compared to the normal population,
particularly among those receiving total body irradia-
tion (TBI) containing conditioning regimens. These
women had higher rates of cesarean section, preterm
delivery, and low birth weight infants compared to
the normal population. Partners of male HCT recipi-
ents had uncomplicated pregnancies. In 2006, the
BMTSS reported on pregnancy outcomes of 619
HCT survivors or their partners [4]. Data was collected
via a mailed questionnaire to participants in the study
and their siblings. There were 54 pregnancies reported
from 34 patients (26 male, 8 female), with 46 live births.
Compared to their siblings, HCT survivors had a lower
prevalence of conception, but if pregnancy did occur,
outcome was likely to be favorable. Risk factors for
reporting inability to conceive a pregnancy after trans-
plant included female sex of the HCT recipient, age at
HCT .30 years, and use of TBI in conditioning.
We report a large case series of pregnancies after
autologous and allogeneic HCT that were reported
to the Center for International Blood and Marrow
Transplant Research (CIBMTR). Our study describesassociations of conditioning regimen, age, and disease
with pregnancy after HCT.METHODS
Data for this study were obtained from the
CIBMTR, which is a voluntary group of more than
500 transplant centers worldwide. Participating cen-
ters register basic information on all consecutive
HCTs to a Statistical Center at the Medical College
of Wisconsin. Detailed demographic and clinical
data are collected on a representative sample of regis-
tered patients using a weighted randomization scheme.
Patients are followed longitudinally, with yearly
follow-up. Observational studies conducted by the
CIBMTR during the time period of this study were
done with a waiver of informed consent and are com-
pliant with HIPAA regulations as determined by the
institutional review board and the Privacy Officer of
the Medical College of Wisconsin.
From 2002 to 2007, the CIBMTR requested that
centers report whether a transplant recipient or the re-
cipient’s partner became pregnant during post-HCT
follow-up. Patients could have received a transplant
at any time prior to 2007. Our study describes disease
and transplant characteristics of the HCT recipients
who reported a pregnancy during this time period.
Data for these analyses were limited to the representa-
tive sample of patients on whom CIBMTR requests
detailed report forms and we did not contact centers
for providing supplemental data about reported preg-
nancies. The date of conception was not collected on
CIBMTR forms and was imputed as the median time
point between 2 successive follow-up reports submit-
ted before and after pregnancy. This is a descriptive
case series only, and no comparative statistical analyses
were planned for this study.RESULTS
Our cohort included 178 patients for whom a preg-
nancy was reported to the CIBMTR during the study
period. These included 83 female HCT recipients and
female partners of 95 male HCT recipients (Tables 1
and 2). In this cohort, 99 patients (34 women, 65 men)
were transplanted for a malignant disorder and 79
patients (49 women, 30 men) were transplanted for
a nonmalignant disorder. The group transplanted for
malignancy comprised 97 patients with a hematologic
malignancy, primarily acute leukemia (N 5 35, 10
women, 25 men), and chronic myelogenous leukemia
(CML; N 5 25, 3 women, 22 men), as well as 2
patients with solid cancers. The group transplanted
for nonmalignant disorders included 75 patients with
Table 1. Characteristics of Men Whose Partners Reported Pregnancy after Hematopoietic Cell Transplantation
Malignant Diseases
Characteristic Autologous N (%)
Allogeneic
Myeloablative N (%)
Allogeneic
Nonmyeloablative N (%)
Nonmalignant
diseases N (%)
Number of patients 13 50 2 30
Median age at HCT (range), years 28 (20-40) 25 (5-53) (30-49) 22 (4-34)
Age at HCT, years
<10 0 1 (2) 0 2 (7)
10-19 1 (8) 5 (10) 0 9 (30)
20-29 7 (54) 32 (64) 1 14 (47)
30-39 4 (31) 11 (22) 0 5 (17)
40-49 1 (8) 0 1 0
$50 0 1 (2) 0 0
Diagnosis
Acute myelogenous leukemia† 2 (15) 17 (34) 1 0
Acute lymphoblastic leukemia† 1 (8) 5 (10) 0 0
Chronic myelogenous leukemia 0 22 (44) 0 0
Myelodysplastic syndrome 0 5 (10) 1 0
Lymphoma 7 (53) 1 (2) 0 0
Multiple myeloma 1 (8) 0 0 0
Solid cancer 2 (15) 0 0 0
Severe aplastic anemia 0 0 0 30 (100)
Chemotherapy prior to conditioning regimen 13 (100) 45 (96) 2 0
Radiation therapy prior to conditioning regimen 3 (23) 0 0 0
Year of HCT
#1989 0 6 (12) 0 5 (17)
1990-1994 2 (15) 17 (34) 0 12 (40)
1995-1999 6 (46) 13 (26) 0 5 (17)
$2000 5 (38) 14 (28) 2 8 (27)
Conditioning regimen
TBI + cyclophosphamide ± other 0 14 (28) 0 0
Busulfan + cyclophosphamide ± other‡ 2 (15) 32 (64) 0 5 (17)
Cyclophosphamide ± other (no TBI or busulfan) 8 (62) 0 1 24 (80)
Other 3 (23) 4 (8) 1 1 (3)
TBI in conditioning
Median dose (range), cGy 1320 1200 (400-1440) 200 —
TBI dose, cGy
No TBI 12 (92) 33 (66) 1 30 (100)
<400 0 0 1 —
400-800 0 3 (6) 0 —
>800 1 (8) 14 (28) 0 —
Cyclophosphamide dose, mg/kg
No cyclophosphamide 3 (23) 4 (8) 1 1 (3)
#120 2 (15) 30 (63) 1 4 (13)
>120 8 (62) 14 (29) 0 25 (83)
Missing 0 2 0 0
Donor type
Autologous 13 (100) 0 0 0
HLA-matched siblings 0 37 (74) 2 28 (90)
Other related 0 3 (6) 0 1 (3)
Unrelated donor 0 10 (20) 0 1 (3)
Acute GVHD at any time after HCT — 17 (34) 0 4 (13)
Chronic GVHD at any time after HCT — 29 (58) 1 11 (37)
Relapse after HCT* 5 (38) 10 (20) 1 —
Median time from HCT to relapse (range), months 7 (<1-62) 17 (<1-144) 1 —
Second transplant or DLI for relapse 2 (15) 3 (6) 1 0
Disease status at last followup
Continued complete remission 8 (62) 40 (80) 1 0
Complete remission after relapse 1 (8) 9 (18) 0 0
Recurrent disease 4 (31) 1 (2) 1 0
Cured 0 0 0 30 (100)
Median followup (range), years 8 (2-15) 10 (3-19) (2-5) 11 (2-22)
HCT indicates hematopoietic cell transplantation; TBI, total body irradiation; GVHD, graft-versus-host disease; DLI, donor lymphocyte infusion.
*For malignant diseases only.
†A total of 18/20 patients with acute myelogenous leukemia and 5/6 patients with acute lymphoblastic leukemia had received HCT in first complete
remission.
‡Among 32 men who received myeloablative busulfan + cyclophosphamide6 other as conditioning, 5 (16%) reported use of cryo-preserved sperm, 17
(53%) fathered a child naturally and information about sperm storage was missing in 10 (31%).
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Table 2. Characteristics of Women Who Reported Pregnancy after Hematopoietic Cell Transplantation
Malignant Diseases
Characteristic Autologous N (%)
Allogeneic
Myeloablative N (%)
Allogeneic
Nonmyeloablative N (%)
Nonmalignant
diseases N (%)
Number of patients 20 12 2 49
Median age at HCT (range), years 22 (16-33) 21 (9-33) (24-33) 18 (5-32)
Age at HCT, years
<10 0 2 (17) 0 3 (6)
10-19 8 (40) 3 (25) 0 26 (53)
20-29 8 (40) 6 (50) 1 19 (39)
30-39 4 (20) 1 (8) 1 1 (2)
Diagnosis
Acute myelogenous leukemia‡ 2 (10) 4 (33) 0 0
Acute lymphoblastic leukemia‡ 0 4 (33) 0 0
Chronic myelogenous leukemia 0 3 (25) 0 0
Myelodysplastic syndrome 0 1 (8) 0 0
Lymphoma 18 (90) 0 0 0
Multiple myeloma 0 0 1 0
Severe aplastic anemia 0 0 0 45 (92)
Immune deficiency disorder 0 0 0 1 (2)
Other† 0 0 1 3 (6)
Chemotherapy pre-HCT 20 (100) 11 (92) 2 45 (92)
Radiation therapy pre-HCT 10 (100) 0 0 0
Year of HCT
#1989 0 2 (17) 0 8 (16)
1990-1994 7 (35) 3 (25) 0 9 (18)
1995-1999 7 (35) 6 (50) 0 15 (31)
$2000 6 (30) 1 (8) 2 17 (35)
Conditioning regimen
TBI + cyclophosphamide ± other 0 9 (75) 0 4 (8)
Busulfan + cyclophosphamide ± other 1 (5) 3 (25) 0 1 (2)
Cyclophosphamide ± other (no TBI or busulfan) 15 (75) 0 0 43 (88)
Other 4 (20) 0 2 1 (2)
TBI in conditioning
Median dose (range), cGy — 1200 (500-1440) — 200 (200-300)
TBI dose, cGy
No TBI 20 3 (25) 2 45 (94)
<400 0 0 0 3 (6)
400-800 0 1 (8) 0 0
>800 0 8 (67) 0 0
Missing 0 0 0 1
Cyclophosphamide dose, mg/kg
No cyclophosphamide 4 (20) 0 2 1 (2)
#120 4 (20) 7 (58) 0 4 (8)
>120 12 (60) 5 (42) 0 43 (90)
Missing 0 0 0 1
Donor type
Autologous 20 0 0 0
HLA-matched Siblings 0 9 (75) 2 42 (86)
Other related 0 1 (8) 0 1 (2)
Unrelated donor 0 2 (17) 0 6 (12)
Acute GVHD at any time after HCT — 6 (50) 0 6 (12)
Chronic GVHD at any time after HCT — 5 (42) 0 10 (20)
Relapse after HCT* 1 (5) 1 (8) 1 —
Median time from HCT to relapse, months 36 1 3
Second transplant or DLI for relapse 0 0 1 5 (10)
Disease status at last followup
Continued complete remission 19 (95) 11 (92) 1 0
Complete remission after relapse 0 1 (8) 0 0
Recurrent disease 1 (5) 0 1 0
Cured 0 0 0 48 (100)
Missing 0 0 0 1
Median followup (range), years 9 (3-15) 10 (5-20) (3-4) 9 (1-23)
HCT indicates hematopoietic cell transplantation, TBI, total body irradiation; GVHD, graft-versus-host disease; DLI, donor lymphocyte infusion.
*For malignant diseases only.
†Includes chronic lymphocytic leukemia (N 5 1), thalassemia (N 5 1), and histiocytic disorders (N 5 2).
‡A total of 4/6 patients with acute myelogenous leukemia and 1/4 patients with acute lymphoblastic leukemia had received HCT in first complete
remission.
160 Biol Blood Marrow Transplant 17:157-166, 2011A. W. Loren et al.
Biol Blood Marrow Transplant 17:157-166, 2011 161Pregnancy after HCTsevere aplastic anemia (SAA; 45 women, 30 men)
and 4 patients with other conditions (thalassemia,
histiocytic disorders, and immune deficiency disorder).
Among patients transplanted for malignancy, 33
received an autologous (13 women, 20 men), 62
received a myeloablative (MA) allogeneic (12 women,
50 men) and 4 received a nonmyeloablative (NMA)
allogeneic (2 women, 2 men) transplant.
Thirty-two patients receivedTBI, 23 of whomwere
at MA doses (.800 cGy). Although details regarding
dose and duration of radiation treatment prior to
HCTwerenot available, nopatient had received cranio-
spinal irradiation.Twelve patients (6women, 6men) re-
ported a pregnancy aftermultiple transplants, includingTable 3. Recipient Characteristics at the Time of Pregnancy
Characteristic Autologous N (%)
Men who fathered a child after HCT
N 13
Median age at pregnancy (range), years 32 (23-48)
Age at pregnancy, years
<20 0
20-29 2 (15)
30-39 9 (69)
40-49 2 (15)
$50 0
Median time from HCT to pregnancy (range), years 7 (1-12)
Time from HCT to pregnancy, years
<3 4 (31)
3-5 0
5-10 8 (62)
>10 1 (8)
Fathered a child
Using cryopreserved sperm 0
Naturally 9 (69)
Unknown 4 (31)
Partner had a live birth
Yes 12 (92)
No 1 (8)
Unknown 0
Women who reported pregnancy after HCT
N 20
Median age at pregnancy (range), years 28 (18-40)
Age at pregnancy, years
<20 1 (5)
20-29 13 (65)
30-39 5 (25)
40 1 (5)
Median time from HCT to pregnancy (range), years 6 (1-15)
Time from HCT to pregnancy, years
<3 4 (20)
3-5 3 (15)
5-10 9 (45)
>10 4 (20)
Partner fathered a child
Using cryopreserved sperm 0
Naturally 1 (5)
Unknown 19 (95)
Had a live birth
Yes 18 (90)
No 0
Unknown 2 (10)
HCT indicates hematopoietic cell transplantation.2 patients who had received 3 transplants (1 female
patient received 2 autologous HCT followed by an
HLA-matched sibling donor HCT for multiple mye-
loma and a male patient received 3 HLA-matched
sibling donor HCT for CML). For the 6 men whose
partners reported pregnancy after multiple transplants,
1 had used cryopreserved sperm to facilitate conception;
information on whether cryopreserved sperm was used
was missing for the other 5 patients.
Table 3 describes characteristics of recipients for
whom a pregnancy was reported to the CIBMTR. Age
at the time of pregnancy ranged from 15 to 40 years in
women and 18 to 55 years among men whose partners
became pregnant. Pregnancies were reported to occurMalignant Diseases
Allogeneic
Myeloablative N (%)
Allogeneic
Nonmyeloablative N (%)
Nonmalignant
diseases N (%)
50 2 30
33 (18-55) (35-51) 31 (19-47)
1 (2) 0 1 (3)
18 (36) 0 12 (40)
23 (46) 1 15 (50)
7 (14) 0 2 (7)
1 (2) 1 0
7 (1-17) (2-5) 9 (2-20)
11 (22) 1 2 (7)
7 (14) 1 6 (20)
20 (40) 0 9 (30)
12 (24) 0 13 (43)
14 (28) 0 1 (3)
21 (42) 1 23 (77)
15 (30) 1 6 (20)
38 (76) 1 27 (90)
10 (20) 1 1 (3)
2 (4) 0 2 (7)
12 2 49
29 (18-39) (25-34) 27 (15-37)
2 (17) 0 8 (16)
6 (50) 1 26 (53)
4 (33) 1 15 (31)
0 0 0
7 (3-18) 1 7 (1-20)
1 (8) 2 15 (31)
1 (8) 0 3 (6)
6 (50) 0 16 (33)
4 (33) 0 15 (31)
0 0 0
3 (25) 0 11 (22)
9 (75) 2 38 (78)
9 (75) 1 39 (80)
3 (25) 1 8 (16)
0 0 2 (4)
Table 4. Pregnancy after Hematopoietic Cell Transplantation: Distribution of Age at Transplant with Dose of Total Body Irradi-
ation, Dose of Cyclophosphamide during Conditioning, and Diagnosis
Age at HCT in years, N (%)
Characteristic <10 10-19 20-29 30-39 $40
Men who fathered a child after HCT, N
N 3 15 54 20 3
Dose of TBI
No TBI 3 (100) 13 (87) 42 (78) 16 (80) 2 (67)
<400 cGy 0 0 0 0 1 (33)
400-799 cGy 0 1 (7) 2 (4) 0 0
800-1199 cGy 0 1 (7) 8 (15) 4 (20) 0
$1200 cGy 0 0 2 (4) 0 0
Conditioning regimen cyclophosphamide dose
No cyclophosphamide 0 0 6 (12) 2 (10) 1 (33)
#120 mg/kg 1 (33) 5 (33) 23 (44) 6 (30) 2 (67)
121-200 mg/kg 1 (33) 8 (53) 20 (38) 12 (60) 0
>200 mg/kg 1 (33) 2 (13) 3 (6) 0 0
Diagnosis
Malignant disorder 1 (33) 6 (40) 40 (74) 15 (75) 3 (100)
Nonmalignant disorder 2 (66) 9 (60) 14 (26) 5 (25) 0
Women who reported pregnancy after HCT, N
N 5 36 34 7 0
Dose of TBI
No TBI 3 (60) 33 (92) 28 (82) 6 (86) 0
<400 cGy 0 0 3 (9) 0 0
400-799 cGy 0 1 (3) 0 0 0
800-1199 cGy 1 (20) 2 (6) 3 (9) 1 (14) 0
$1200 cGy 1 (20) 0 0 0 0
Conditioning regimen cyclophosphamide dose
No cyclophosphamide 0 1 (3) 5 (15) 1 (14) 0
#120 mg/kg 2 (40) 5 (14) 6 (18) 2 (29) 0
121-200 mg/kg 2 (40) 26 (72) 16 (47) 4 (57) 0
>200 mg/kg 1 (20) 4 (11) 7 (21) 0 0
Diagnosis
Malignant disorder 2 (40) 11 (30) 15 (44) 6 (86) 0
Nonmalignant disorder 3 (60) 26 (70) 19 (56) 1 (14) 0
HCT indicates hematopoietic cell transplantation; TBI, total body irradiation.
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reported use of cryopreserved sperm, but these data
were missing in another 26 of 95 men who fathered
a child post-HCT. Information regarding use of cryo-
preserved embryos ordonoroocytes in female transplant
recipients was not collected on the CIBMTR follow-up
forms. Centers reported on whether a pregnancy re-
sulted in a ‘‘live birth’’ for 169 patients; 67 of 79 (85%)
pregnancies in female HCT recipients and 78 of 91
(86%) pregnancies in female partners of male HCT re-
cipients resulted in live births. We do not have data on
the cause or timing of unsuccessful pregnancies or on
pre-, peri-, or postnatal maternal or fetal complications.
The distribution of age at transplantation of the
cohort with dose of TBI, dose of cyclophosphamide
(Cy) in the conditioning regimen, and diagnosis is
shown in Table 4. Forty-two women (50%) and 18
men (19%) had received their transplant before the
age of 20 years. Overall, although the majority of preg-
nancies were reported among women and partners of
men who had not received TBI as part of conditioning,
some pregnancies did occur, even among patients who
had received MA doses of TBI and/or Cy.The median time to pregnancy after autologous
HCT was 6 years in women and 7 years in partners
of men (Table 3). In both women and partners of
men receiving MA HCT for malignancy the median
time to pregnancy was 7 years after HCT. The median
time to pregnancy among NMA HCT recipients for
malignant disorders was 1 year post-HCT for women
and 3.5 years for partners of men. The median time to
pregnancy among partners of female recipients and
male recipients of HCT for nonmalignant diseases
was 7 and 9 years, respectively. These time periods
are consistent with the observation that spermatogen-
esis recovers in 20% to 25% of HCT patients after
prolonged follow-up, even after TBI-based regimens
[16,17], and thus longer follow-up is important when
attempting to fully capture fertility and pregnancy.
Among 34 women who received HCT for a malig-
nant disorder, 3 relapsed between HCT and pregnancy
(1 autologous, 1 MA allogeneic, and 1 NMA allogeneic
HCT); 1 was in remission and 2 had persistent disease
at the time of pregnancy (Hodgkin lymphoma andmul-
tiple myeloma). No relapse occurred during or after
pregnancy in these women. Eight patients (7 men, 1
Biol Blood Marrow Transplant 17:157-166, 2011 163Pregnancy after HCTwoman) died following pregnancy. Relapse was the
most common cause of death (N 5 5).DISCUSSION
Our study provides further evidence that some
autologous and allogeneic HCT recipients have pre-
served fertility, including patients who receive HCT
at age\20 years and those who receive MA doses of
TBI and/or Cy.
Pregnancy afterHCThas been reported previously;
the relatively large case series that are published in the
literature are summarized in Table 5 [4,11-13]. Taken
together, these previous studies and our present study
indicate that fertility is most frequently preserved in
patients receiving a transplant in the young adult age
group (15-30 years), although some patients who
received HCT as young as \5 years of age have
become pregnant or fathered a child as adults. Among
patients whose fertility was maintained, most received
anon-TBI-based conditioning regimen.However, there
were some pregnancies reported by partners of men and
by women who received very high doses of TBI and/or
Cy as part of their HCT conditioning regimens. Preg-
nancy occurred despite the presence of chronic graft-
versus-host disease (cGVHD), indicating that cGVHD
and its therapiesmaynot always impair fertility.Thema-
jority of reported pregnancies occurred within 5 to 10
years after transplantation, but some occurred within
the first year posttransplant. This observation has clear
and potentially unrecognized implications for counsel-
ingpatients aboutusingcontraceptioneven in the imme-
diate posttransplant period.
We could not address the risks of maternal or fetal
complications in our study, but the literature (as summa-
rized in Table 5) suggests that these complications may
occur at an increased rate in female HCT recipients;
hence, posttransplant pregnancies should be considered
high risk. Nevertheless, pregnancies in this population
are very likely to result in a live birth. Importantly, no in-
crease in the risk of congenital malformations has been
observed in other published studies [4,10,12,13]. The
frequency of preterm births and of low or very low
birth weight infants has been reported as increased in
some [12,13], but not all prior series [4]. Our study was
not able to address this issue.
The effect of NMA preparative regimens on fertil-
ity preservation is unknown.As these regimenswere in-
troduced within the last decade, previous studies did
not report on pregnancy outcomes in NMA HCT
recipients. Our study included 4 patients who reported
pregnancy after NMA HCT. Although typically used
in patients over the age of 40 to 50 years, lesser intensity
conditioning regimens have been increasingly used
among younger patients, especially for those with
low-grade lymphoid malignancies and nonmalignantdisorders. Because the effect of chemotherapy and
TBI on gonadal function is dose dependent [7-9]
young patients who undergo HCT using NMA
conditioning regimens may be expected to have
a higher likelihood of preserving fertility compared to
recipients of conventional MA regimens. On the
other hand, any potential advantages to fertility
preservation among young patients receiving NMA
preparative regimen may be offset by extensive prior
therapy that may have had an adverse impact on
fertility. With recent data indicating that HCT
outcomes may be similar between reduced intensity
and MA transplant regimens for certain disorders
[18-20], the possibility of retaining fertility may be
a reason to select NMA conditioning, even in
younger patients who typically can withstand MA
therapy. The impact of NMA conditioning on
fertility warrants further prospective investigation.
Another noteworthy feature of our study is the large
proportion of patients transplanted with nonmalignant
diseases, specifically SAA, which comprised 42% of
reported pregnancies. SAA patients generally have not
received cytotoxic agents or radiation prior to HCT,
and the conditioning regimens used for SAA commonly
utilize lower doses of alkylating agents such as Cy.
Hence, Cy as part of conditioning regimen may be rel-
atively less gonadotoxic if the patient has not received
any prior alkylator or other gonadotoxic therapies.
Again, this observation has particularly important ram-
ifications for contraceptive counseling posttransplanta-
tion in these patients.
Options to preserve fertility are available to patients
preparing to undergo HCT. For men, cryopreservation
of sperm is standard of care and is readily available in
most areas. Barriers may include psychologic distress
and costs. In women, options are fewer, more invasive
and mostly investigational. A commonly utilized option
is for the patient to undergo oocyte stimulation and re-
trieval, a semi-invasive surgical procedure, followed by
in vitro fertilization and cryopreservation of embryos.
This requires either a male partner or a willingness on
the patient’s part to fertilize her eggs with donor sperm.
Experimental options include oocyte cryopreservation
(without fertilization), or removal of all or part of the
ovary for cryopreservation and reimplantation at a later
date.Oncofertility, or the use of reproductive technology
for cancer patients, is a new and rapidly growing area be-
cause of the efforts of federal and patient advocacy orga-
nizations (eg, NIH-funded Oncofertility Consortium
and Fertile Hope, now part of the Lance Armstrong
Foundation). Improving access to both standard and in-
vestigational fertility preservation techniques before
transplant is an important and increasingly necessary
part of pretransplant counseling, which can have a long-
lasting impact on quality of life after transplantation.
Our reportmost likelyunderestimates the trueprev-
alence of conception andpregnancy afterHCTpartially
Table 5. Review of Representative Large Case Series of Pregnancy after Hematopoietic Cell Transplantation
Reference N*
Age at HCT
in Years,
Median (Range)
Age at First Pregnancy
in Years,
Median (Range)
Time between HCT and
pregnancy in Years,
Median (Range)
TBI in
Conditioning, N (%)
Cyclophosphamide
in Conditioning,
N (%) Remarks
Allogeneic HCT
Sanders et al. (1996) [13] Women 5 41 18 (4-34) 24 (16-36) – (<1-17) 13 (32%) 41 (100%) – 115/146 (79%) pregnancies resulted in live
births
– Rates of abortion and congenital
abnormalities no greater than general
population rates
– Greater than expected rates of preterm
deliveries and low birth weight infants in
female HCT recipients
– TBI increased risk of abortion
Men 5 35 22 (11-42) 33 (24-52) – (<1-18) 5 (14%) 35 (100%)
Salooja et al. (2001) [12] Women 5 74 19 (6-36) — 6 (<1-13) 32 (43%) 68 (92%) – 271/312 (87%) pregnancies resulted in live
births
– Rates of congenital abnormalities no greater
than general population rates
– TBI increased risk of maternal complications
in female recipients of allogeneic HCT
Men 5 93 25 (10-45) — 5 (1-20) 21 (23%) 65 (70%)
Carter et al. (2006) [4] Women 5 4 22 (21-30) 26 (23-28) — 3 (75%) 3 (75%) – 46/54 (85%) pregnancies resulted in live births
– Likelihood of live birth, miscarriage, and
stillbirth similar to sibling controls
– Limited to adult HCT recipients
Men 5 18 27 (21-35) 31 (25-43) — 13 (72%) 14 (78%)
Autologous HCT
Jackson et al. (1997) [11] Women 5 10 25 (23-36) — 2 (1-6) 0 0 – 13/13 (100%) pregnancies resulted in live
births
– All patients received melphalan ± etoposide
conditioning
– No congenital abnormalities observed
– Limited to adult HCT recipients
Salooja et al. (2001) [12] Women 5 39 24 (18-33) — 3 (<1-18) 3 (8%) 5 (13%) – Salooja et al., vide supra
Men 5 26 27 (15-33) — 4 (1-13) 3 (12%) 10 (39%)
Carter et al. (2006) [4] Women 5 4 27 (25-30) 31 (29-33) — 2 (50%) 4 (100%) – Carter et al., vide supra
Men 5 8 30 (23-37) 34 (27-40) — 2 (25%) 8 (100%)
HCT indicates hematopoietic cell transplantation; TBI, total body irradiation.
*Women who reported pregnancy or men who fathered a child.
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Biol Blood Marrow Transplant 17:157-166, 2011 165Pregnancy after HCTbecause of reporting issues, but alsobecause of early first
trimester pregnancy losses that may not be recognized
or reported. Pregnancies often occur years after trans-
plantation, and patients may no longer be followed pri-
marilyby the transplant center, thus limiting the capture
of these data. Furthermore, it would not be unusual for
obstetric care to occur at a place other than the trans-
plant center. Also, patients may not have reported con-
ceptions that were voluntarily terminated or resulted
in a spontaneous abortion. We have no information
regarding several important factors such as pre-HCT
treatment exposures, pre-HCT fertility preservation
techniques (eg, pelvic shielding during prior radiation
or TBI), use of ART, or maternal and fetal complica-
tions. Among men whose partners reported pregnancy,
information on whether cryopreserved sperm was used
to facilitate conception was missing for 26 of 95 (27%)
patients. Finally, because of lack of understanding about
which patients are truly of child-bearing age andmay be
interested in conceiving children, the incidence of pre-
served fertility cannotbeestimatedusing the current ob-
servational data.TheEBMThas reportedonpregnancy
after HCT in 2001 [12]; 39 cases from Europe were in-
cluded in our study, and some of these cases may also
have been reported in the previous EBMT study.
Notwithstanding these limitations, our large case
series of pregnancies after HCT highlights that fertility
may be preserved in selected patients; including patients
who were very young at the time of transplant, those
who received MA TBI or high-dose alkylator-based
conditioning, and those who have undergone more
than 1HCT.We recommend that all patients of repro-
ductive age or younger should be counseled about fertil-
ity, contraception, and family planning, both before and
after HCT, with particular emphasis on fertility preser-
vation strategies available both routinely and on an
investigational basis before transplantation. Fertility
andoutcomesofpregnancy afterHCTneedprospective
evaluation in large transplant cohorts.ACKNOWLEDGMENTS
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